Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Trabectedin (Primary) ; Dexamethasone; Dexamethasone; Ondansetron
Indications Cancer metastases; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Meningioma; Myxoid liposarcoma; Nerve sheath neoplasms; Neurofibrosarcoma; Sarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
Focus Therapeutic Use
Acronyms TRASTS

29 May 2023 Planned number of patients changed from 96 to 199.
06 Jun 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2028.
06 Jun 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com